{"name":"ALRA","slug":"alra","ticker":"","exchange":"","domain":"alra.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharmaceuticals","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"1971-01-01","label":"Azo Gantrisin first approved","drug":"Azo Gantrisin","drugSlug":"sulfafurazole","type":"approval","sentiment":"positive"},{"date":"1972-01-01","label":"Dimenhydrinate first approved","drug":"Dimenhydrinate","drugSlug":"dimenhydrinate","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Azo Gantrisin","genericName":"sulfafurazole","slug":"sulfafurazole","indication":"Acute otitis media","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Dimenhydrinate","genericName":"DIMENHYDRINATE","slug":"dimenhydrinate","indication":"Motion sickness","status":"marketed"}]}],"pipeline":[{"name":"Azo Gantrisin","genericName":"sulfafurazole","slug":"sulfafurazole","phase":"marketed","mechanism":"Endothelin-1 receptor","indications":["Acute otitis media","Chancroid","Chlamydia Cervicitis","Chlamydial conjunctivitis","Falciparum malaria"],"catalyst":""},{"name":"Dimenhydrinate","genericName":"DIMENHYDRINATE","slug":"dimenhydrinate","phase":"marketed","mechanism":"Histamine H1 receptor","indications":["Motion sickness"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":0,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}